We investigated several clinical and immunologic outcomes of interest stratified by CD16A genotype: anti–SARS-CoV-2 IgG titers, nasal viral load, COVID-19 severity, respiratory status, ICU admission, mechanical ventilation, and death. This evidence concerns the gene FCGR3A and COVID-19.